Viewing nowEmpahuna Tablet 25 mg (Empagliflozin)
Empagliflozin 25mg
Tablet · Prescription medication
Aprogen Pharmaceuticals, Co., Ltd.

MFDS item code 202102374 · Approved 2021.03.16 · Insurance code 645210970
Improvement of glycemic control in adults with type 2 diabetes mellitus
This drug is used as an adjunct to diet and exercise to help control blood sugar in adults with type 2 diabetes and is administered alone, or in combination therapy in various cases. It improves blood sugar control when used in combination with metformin when monotherapy is insufficient, or with metformin and pioglitazone, sulfonylureas, insulin, and the DPP-4 inhibitor linagliptin. It effectively manages blood sugar, especially in patients with difficult blood sugar control, and precautions should be noted for patients with cardiovascular disease. This drug is used for the treatment of type 2 diabetes.
The recommended dose of this medicine is 10 mg once daily, whether used as monotherapy or as add-on combination therapy with other antihyperglycemic agents, such as insulin. If 10 mg of this medicine is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is administered with a sulfonylurea or insulin, reducing the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, section 3, Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Special populations • Patients with renal impairment No dosage adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistently reduced glomerular filtration rate of < 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. Discontinue this medicine if the glomerular filtration rate decreases to < 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those on dialysis, as efficacy is not expected. • Patients with hepatic impairment No dosage adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. • Older adults No dosage adjustment based on age is necessary. Renal function and the risk of volume depletion should be considered in patients aged 75 years or older. Initiation of this medicine is not recommended in patients aged 85 years or older because clinical experience is limited (see Precautions for Use, section 4, General Precautions).
This drug should not be administered to patients with allergies to the active ingredient or its components. This drug is not used in patients with type 1 diabetes or diabetic ketoacidosis. It is safe not to use this drug in patients with severely impaired kidney function, end-stage kidney disease, or those undergoing dialysis. This drug contains lactose and should not be given to patients with lactose intolerance, galactose intolerance, or hereditary lactase deficiency. In patients with mildly impaired kidney function, cautious use is required as this drug's dosage may need adjustment or discontinuation. Use is not recommended in patients with moderate or severe heart failure, and caution is needed in mild cases. When used with medications like insulin or sulfonylureas, dosage adjustments may be necessary due to the risk of hypoglycemia. This drug helps with blood sugar control, but hypoglycemic symptoms may occur, so symptoms should be monitored. The risk of genital infections or urinary tract infections may increase, so immediate consultation with a doctor is necessary if infection symptoms occur. This drug increases urine output, which may lead to more frequent urination, requiring preparation for this effect. There may be risks of hypotension or dehydration due to reduced fluid volume, particularly caution is needed for elderly patients or those with low blood pressure. Serious metabolic abnormalities like ketoacidosis may occur, so immediate treatment is necessary if symptoms appear. There is a possibility of liver damage, so inform medical personnel immediately if symptoms of liver dysfunction appear. This drug may pose a risk of hypoglycemia while driving or operating machinery, so caution is warranted. It is advisable to avoid using this drug during pregnancy or when planning to become pregnant, and it is also safe not to use it while breastfeeding. It is not used in children under 18 years of age as safety and efficacy have not been established. No specific toxic symptoms have been reported in case of overdose, but appropriate treatment should be received immediately if overdose occurs. This drug may interact with other medications, so inform medical personnel if you are currently taking any medications. When storing, keep it out of reach of children and do not transfer it to other containers. During treatment with this drug, regular checks of kidney function and blood sugar status should be conducted to monitor for abnormalities.
Not everyone experiences these, and they can vary from person to person.
This drug may be sensitive to air and moisture, so it must be stored in a tightly sealed container. Additionally, it is best kept at room temperature between 1 and 30 degrees Celsius. Avoid extremely hot or cold places for safe storage.
Light yellow, double-convex oval film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowEmpagliflozin 25mg
Tablet · Prescription medication
Aprogen Pharmaceuticals, Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.